Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alvelestat - Mereo BioPharma

Next Previous
Search
Drug Profile

Alvelestat - Mereo BioPharma

Alternative Names: AZD-9668; MPH-966

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Allegheny Singer Research Institute; AstraZeneca; Mereo BioPharma; National Cancer Institute (USA)
  • Class Amides; Anti-infectives; Anti-inflammatories; Antibronchitics; Antifibrotics; Antihyperglycaemics; Bronchodilators; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes
  • Available For Licensing Yes - Alpha 1-antitrypsin deficiency

Highest Development Phases

  • Phase II Alpha 1-antitrypsin deficiency; Type 2 diabetes mellitus
  • Phase I/II Bronchiolitis obliterans; COVID-19 respiratory infection
  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 05 Mar 2025 Alvelestat - Mereo BioPharma receives Orphan Drug status for Alpha 1-antitrypsin deficiency in European Union
  • 12 Jan 2025 EMA's COMP issues positive opinion for ODD of alvelestat in Alpha 1-antitrypsin deficiency
  • 12 Jan 2025 Mereo BioPharma expects EC's final decision on ODD of alvelestat in alpha 1-antitrypsin deficiency by Q1 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top